Gilenya and Skin Cancer Risk
Gilenya (fingolimod) carries warnings for patients with a history of skin cancer due to observed cases of basal cell carcinoma (BCC) and melanoma in clinical trials and post-marketing data. The prescribing information notes 81 cases of BCC among 3,766 fingolimod-treated patients (2.1%) versus 18 among 2,230 placebo patients (0.8%), and 9 melanoma cases (0.2%) versus none in placebo.[1] The FDA label advises caution, recommending dermatologic screening before starting and periodic monitoring during treatment, especially for those with prior malignancies.[1]
Official Recommendations for Patients with History
Novartis, Gilenya's manufacturer, and the label state it's not recommended for patients with a history of malignancy—active or resolved—unless benefits outweigh risks, as assessed by a physician. No absolute contraindication exists for skin cancer specifically, but heightened vigilance is required. Discontinue if new skin cancers develop.[1][2]
Clinical Trial Data on Skin Cancers
In pooled multiple sclerosis trials (up to 4.5 years), fingolimod showed higher incidence rates: BCC at 6-10 cases per 1,000 patient-years versus 3-4 for placebo; squamous cell carcinoma at 1-2 versus <1; melanoma at 0.5-1 versus 0. FREEDOMS and TRANSFORMS studies reported similar patterns, prompting label updates.[1][3] Long-term extensions (up to 10 years) confirm persistent risk, though rates stabilize.[3]
Comparison to Other MS Drugs
| Drug | Skin Cancer Signal? | Key Notes |
|------|---------------------|-----------|
| Gilenya (fingolimod) | Yes (BCC, melanoma) | Highest BCC reports among S1P modulators [1] |
| Tecfidera (dimethyl fumarate) | Yes (higher non-melanoma) | 2023 label update for skin monitoring [4] |
| Ocrevus (ocrelizumab) | Low | Rare cases, no strong signal [5] |
| Kesimpta (ofatumumab) | Minimal | Less data on long-term skin effects [5] |
Gilenya's risk profile stands out among oral MS therapies for BCC.
Patient Monitoring and Alternatives
Screen with full skin exams pre-treatment and every 6-12 months. Sun protection and self-checks are advised. For high-risk patients, neurologists often prefer monoclonal antibodies like Ocrevus, which lack strong skin cancer links.[2][5] Real-world studies (e.g., MSBase registry) show 1.5-2x BCC risk with fingolimod versus interferons.[3]
Regulatory Status and Updates
FDA approved Gilenya in 2010 with skin cancer warnings added in 2011 and strengthened in 2019 based on trial data. EMA mirrors this, requiring cancer history review.[1][6] No recent black box for skin cancer, but ongoing pharmacovigilance.
Sources
[1]: Gilenya Prescribing Information (FDA)
[2]: Novartis Gilenya Safety Info
[3]: Frohman et al., Neurology 2022 (fingolimod long-term safety)
[4]: Tecfidera Label (Biogen)
[5]: Ocrevus/Kesimpta Labels (FDA)
[6]: EMA Gilenya Summary